All In Biotech

Drug Trial Radar · NCT05139017

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Jan 14, 2022

Primary completion

Sep 24, 2027

Study completion Sep 24, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx with respect to progression-free survival (PFS) per Lugano response criteria by blinded independent review committee (BICR); and that ZV in combination with bendamustine rituximab (BR) is superior to BR with respect to PFS per Lugano response criteria by BICR. With protocol amendment 4 (effective: 04-April-2024), enrollment in Cohort B (study arms Bendamustine Rituximab \[BR\] and ZV + BR) is discontinued. No efficacy outcome analysis and hypothesis testing will be conducted for Cohort B.

Conditions

  • DLBCL
  • Diffuse Large B-Cell Lymphoma

Interventions

  • Zilovertamab vedotinBiological

    Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg

  • RituximabBiological

    IV Infusion 375 mg/m\^2

  • GemcitabineDrug

    IV Infusion 1000 mg/m\^2

  • OxaliplatinDrug

    IV Infusion 100 mg/m\^2

  • BendamustineDrug

    IV Infusion 90 mg/m\^2

  • Granulocyte Colony-Stimulating Factor (G-CSF)Drug

    Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experienced dose-limiting toxicities (DLTs) in Part 1Time frame: Up to ~6 weeks
  2. Number of participants who experienced an adverse event (AE)Time frame: Up to ~68 months
  3. Number of participants who discontinued study treatment due to an AETime frame: Up to ~68 months
  4. Overall survival (OS)Time frame: Up to ~35 months
  5. Progression-free survival (PFS)Time frame: Up to ~35 months

Locations

135 sites in 26 countries. Site status is shown where the registry gives one.

  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)

    Glendale, Arizona · Recruiting

  • Beverly Hills Cancer Center ( Site 0184)

    Beverly Hills, California · Active not recruiting

  • Bass Medical Group ( Site 0166)

    Walnut Creek, California · Recruiting

  • Innovative Clinical Research Institute ( Site 0122)

    Whittier, California · Completed

  • Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163)

    Boca Raton, Florida · Recruiting

  • Clermont Oncology Center ( Site 0174)

    Clermont, Florida · Recruiting

  • BRP-Hialeah Hospital ( Site 0182)

    Hialeah, Florida · Recruiting

  • Illinois Cancer Specialists ( Site 8000)

    Niles, Illinois · Recruiting

  • Saint Elizabeth Medical Center Edgewood ( Site 0165)

    Edgewood, Kentucky · Recruiting

  • University of Kentucky Chandler Medical Center ( Site 0158)

    Lexington, Kentucky · Active not recruiting

  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133)

    Louisville, Kentucky · Active not recruiting

  • University of Maryland ( Site 0123)

    Baltimore, Maryland · Active not recruiting

  • Dana-Farber Cancer Institute-Lymphoma ( Site 0111)

    Boston, Massachusetts · Active not recruiting

  • University of Massachusetts Medical School ( Site 0119)

    Worcester, Massachusetts · Active not recruiting

  • Corewell Health ( Site 0162)

    Grand Rapids, Michigan · Recruiting

  • St. Vincent Frontier Cancer Center-Research ( Site 0108)

    Billings, Montana · Completed

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0188)

    Grand Island, Nebraska · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177)

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 0168)

    Las Vegas, Nevada · Recruiting

  • Atlantic Health System ( Site 0116)

    Morristown, New Jersey · Completed

  • Presbyterian Rust Jorgensen Cancer ( Site 9506)

    Rio Rancho, New Mexico · Active not recruiting

  • New York Medical College ( Site 0113)

    Valhalla, New York · Completed

  • Alliance Cancer Specialists (ACS) ( Site 8001)

    Horsham, Pennsylvania · Recruiting

  • Tennessee Cancer Specialists ( Site 7000)

    Knoxville, Tennessee · Recruiting

  • Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156)

    Nashville, Tennessee · Completed

  • Blue Ridge Cancer Care ( Site 0169)

    Roanoke, Virginia · Active not recruiting

  • Instituto Alexander Fleming ( Site 2201)

    CABA, Argentina · Active not recruiting

  • Hospital Italiano de Buenos Aires ( Site 2203)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Active not recruiting

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205)

    Mar del Plata, Buenos Aires, Argentina · Completed

  • Hospital Aleman ( Site 2200)

    Buenos Aites, Buenos Aires F.D., Argentina · Active not recruiting

  • Hospital Privado Universitario de Córdoba ( Site 2202)

    Córdoba, Córdoba Province, Argentina · Active not recruiting

  • Townsville University Hospital ( Site 1800)

    Townsville, Queensland, Australia · Active not recruiting

  • Grampians Health ( Site 1802)

    Ballarat, Victoria, Australia · Recruiting

  • Royal Perth Hospital-Haematology ( Site 1801)

    Perth, Western Australia, Australia · Recruiting

  • Hospital Paulistano ( Site 2300)

    São Paulo, Brazil · Active not recruiting

  • Hospital Erasto Gaertner ( Site 2302)

    Curitiba, Paraná, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 2305)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200)

    Toronto, Ontario, Canada · Completed

  • Biocenter ( Site 2401)

    Concepción, Biobio, Chile · Active not recruiting

  • IC La Serena Research ( Site 2405)

    La Serena, Coquimbo Region, Chile · Active not recruiting

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.